Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited has reported that the U.S. Food and Drug Administration has completed an inspection of its manufacturing facility in Somerset, New Jersey, conducted from April 13 to April 17, 2026, and closed the review with a Form 483 containing three observations. The company said it will address these observations and respond within the required timeframe, underscoring its commitment to maintaining current good manufacturing practice compliance across all its plants, an important factor for sustaining its U.S. market presence and regulatory standing.
More about Lupin Limited
Lupin Limited is a global pharmaceutical company headquartered in India, with operations spanning key markets including the U.S. It focuses on developing, manufacturing, and marketing a broad portfolio of generic and branded formulations, as well as active pharmaceutical ingredients, targeting both regulated and emerging markets.
Average Trading Volume: 30,261
Technical Sentiment Signal: Buy
Current Market Cap: 1069.4B INR
See more insights into LUPIN stock on TipRanks’ Stock Analysis page.